How to Get a Zepbound Prescription: The Complete 2026 Pathway from Eligibility to First Dose

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound requires a prescription from a licensed provider and FDA approval is limited to patients with BMI ≥30 or BMI ≥27 with weight-related comorbidities, though off-label prescribing is common
• The fastest pathway in 2026 is telehealth (48-72 hours from consultation to prescription), compared to 2-4 weeks for traditional in-person appointments with waitlists
• Brand-name Zepbound costs $1,060 per month without insurance, with prior authorization approval rates around 35% for commercial plans, while compounded tirzepatide costs $299-$499 monthly with no prior authorization required
• Compounded tirzepatide became the dominant access pathway in 2024-2026 during the FDA shortage period, accounting for an estimated 60% of all tirzepatide prescriptions written

Direct answer (40-60 words)

Getting a Zepbound prescription requires meeting FDA eligibility criteria (BMI ≥30 or ≥27 with comorbidities), consulting a licensed provider willing to prescribe GLP-1 medications, and navigating either insurance prior authorization (2-4 weeks, 35% approval rate) or paying out-of-pocket. Telehealth platforms offer the fastest pathway, with prescriptions issued within 48-72 hours and compounded tirzepatide available as an alternative.

Table of contents

1. The three pathways to getting tirzepatide prescribed
2. FDA eligibility criteria and how strictly they're enforced
3. What most articles get wrong about BMI requirements
4. The traditional in-person pathway: timeline and costs
5. The telehealth pathway: how it works and who qualifies
6. Insurance prior authorization: the step-by-step process
7. The compounded tirzepatide alternative during the shortage period
8. Required medical screening before any provider can prescribe
9. The FormBlends prescription decision tree
10. State-by-state prescribing restrictions you need to know
11. When you should NOT pursue a Zepbound prescription
12. FAQ
13. Sources

The three pathways to getting tirzepatide prescribed

Every Zepbound prescription in 2026 follows one of three pathways. Understanding which one fits your situation saves weeks of wasted effort.

Pathway 1: Traditional in-person provider. You schedule an appointment with your primary care physician, endocrinologist, or obesity medicine specialist. They evaluate your weight history, order baseline labs (typically A1C, lipid panel, comprehensive metabolic panel), discuss risks and benefits, and write a prescription if you meet criteria. Timeline: 2-4 weeks from first call to prescription in hand, longer if the provider requires multiple visits or specialist referral.

Pathway 2: Telehealth platform. You complete an online intake form, upload recent lab work (if available), and have a video or asynchronous consultation with a licensed provider in your state. If approved, the prescription is sent to a pharmacy within 48-72 hours. Some platforms (including FormBlends) connect you directly to compounding pharmacies. Timeline: 2-7 days from signup to first dose.

Pathway 3: Weight-loss clinic or medical spa. Standalone weight-loss clinics often employ nurse practitioners or physicians who specialize in obesity medicine. They typically offer same-day or next-day prescriptions after an initial consultation. Most operate on a cash-pay model. Timeline: 1-2 weeks from first contact to prescription.

The pathway you choose determines cost, timeline, and whether you'll access brand-name Zepbound or compounded tirzepatide. About 60% of patients in 2026 use pathway 2 (telehealth), 25% use pathway 1 (traditional), and 15% use pathway 3 (weight-loss clinics), based on prescription volume data from IQVIA.

FDA eligibility criteria and how strictly they're enforced

Zepbound received FDA approval in November 2023 for chronic weight management in adults with:

• BMI ≥30 kg/m² (obesity), OR
• BMI ≥27 kg/m² (overweight) with at least one weight-related comorbidity

Approved comorbidities include:

• Type 2 diabetes
• Hypertension
• Dyslipidemia (high cholesterol or triglycerides)
• Obstructive sleep apnea
• Cardiovascular disease

The FDA label also specifies Zepbound is indicated "as an adjunct to a reduced-calorie diet and increased physical activity." This language is standard for all weight-loss medications and doesn't require formal documentation of diet attempts in practice.

How strictly is this enforced?

The FDA sets the labeled indication. Individual providers decide whether to prescribe off-label. In clinical practice:

• Most providers follow the BMI thresholds closely for liability reasons
• The comorbidity requirement at BMI 27-29.9 is enforced inconsistently. Some providers require documented diagnosis codes in your medical record. Others accept patient-reported hypertension or prediabetes.
• Off-label prescribing for BMI 25-26.9 happens but is uncommon. Providers who prescribe below BMI 27 typically document "metabolic syndrome" or "insulin resistance" as justification.
• Prescribing for cosmetic weight loss (patients with BMI <25) is rare and considered outside standard of care by most medical boards

The practical threshold: if your BMI is 27 or above, most telehealth platforms and weight-loss clinics will prescribe without requiring extensive comorbidity documentation. Below 27, you'll need a provider willing to prescribe off-label, which is harder to find.

What most articles get wrong about BMI requirements

Most online content repeats the FDA label (BMI ≥30 or ≥27 with comorbidities) and stops there. The error is assuming this is a hard gate enforced by pharmacies or insurance.

The correction:

Pharmacies don't verify BMI. They fill prescriptions written by licensed providers. If a provider writes a prescription for tirzepatide and you don't meet FDA criteria, the pharmacy will still dispense it. The liability is on the prescriber, not the pharmacy.

Insurance prior authorization does check BMI, but only if you're trying to get coverage. If you're paying cash (either for brand-name Zepbound through a copay card or for compounded tirzepatide), BMI verification doesn't happen at the pharmacy level.

The real enforcement mechanism is provider willingness. Telehealth platforms build BMI checks into their intake forms because they don't want liability exposure. In-person providers have more discretion. A patient with BMI 26.5 and a sympathetic family doctor might get a prescription. The same patient using a telehealth platform with automated eligibility screening won't.

The pattern we see across provider behavior: the more automated the platform, the stricter the BMI enforcement. The more relationship-based the care, the more flexibility.

This matters because patients often waste time applying to platforms where they're automatically rejected, when a single conversation with their primary care physician would have resulted in a prescription.

The traditional in-person pathway: timeline and costs

Step 1: Schedule an appointment. Primary care physicians in most markets are booking 2-4 weeks out for non-urgent appointments as of 2026. Endocrinologists and obesity medicine specialists often have 6-12 week wait times for new patients. If you have an established relationship with a PCP, you can often get a same-week appointment.

Step 2: Initial consultation. The provider will:

• Measure height and weight to calculate BMI
• Review medical history and current medications
• Discuss weight-loss goals and previous attempts
• Order baseline labs (A1C, comprehensive metabolic panel, lipid panel, TSH)
• Screen for contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, history of pancreatitis)

Most providers require lab results before prescribing. Labs take 2-5 business days to result.

Step 3: Follow-up to review labs and write prescription. Some providers write the prescription at the initial visit if you bring recent labs (within 6 months). Others require a follow-up visit after reviewing results. This adds another 1-2 weeks.

Step 4: Insurance prior authorization (if applicable). If using insurance, the provider submits a prior authorization request. Approval takes 3-10 business days for initial review, longer if denied and appealed. See detailed PA process below.

Step 5: Fill prescription. Once approved (or if paying cash), you fill at a retail pharmacy. Brand-name Zepbound is usually in stock at major chains as of April 2026, though spot shortages occurred throughout 2024-2025.

Total timeline: 2-4 weeks for patients with insurance, 1-2 weeks for cash-pay patients with an established provider relationship.

Costs:

• Office visit: $150-$300 without insurance (often covered as preventive care with insurance)
• Labs: $50-$200 without insurance
• Zepbound prescription: $1,060/month list price, $25-$50/month with insurance if prior authorization approved, $550/month with manufacturer savings card (if eligible)

The telehealth pathway: how it works and who qualifies

Telehealth platforms compressed the prescription timeline from weeks to days by removing the scheduling bottleneck and streamlining medical screening.

How the process works:

Step 1: Online intake (10-15 minutes). You complete a medical history questionnaire covering:

• Current height and weight
• Previous weight-loss attempts
• Current medications
• Medical history (thyroid disease, pancreatitis, gallbladder disease, kidney disease)
• Family history of medullary thyroid carcinoma or MEN2

Most platforms auto-calculate BMI and flag ineligible patients immediately.

Step 2: Provider review (24-48 hours). A licensed physician or nurse practitioner in your state reviews your intake form. Some platforms offer live video consultations. Others use asynchronous review (the provider reviews your form and messages you with questions or approval).

Step 3: Prescription issued (same day if approved). If approved, the provider sends a prescription to either:

• A retail pharmacy of your choice (for brand-name Zepbound)
• A compounding pharmacy partnered with the platform (for compounded tirzepatide)

Step 4: Medication shipped or picked up (1-3 days). Compounded tirzepatide is typically shipped overnight or 2-day from the compounding pharmacy. Brand-name Zepbound can be picked up at retail pharmacies same-day if in stock.

Total timeline: 2-7 days from signup to first dose.

Who qualifies:

Telehealth platforms have standardized eligibility criteria:

• Age 18+ (some platforms allow 16+ with parental consent)
• BMI ≥27 in most cases (some require ≥30)
• No contraindications (MTC, MEN2, pregnancy, breastfeeding, active pancreatitis)
• Resident of a state where the platform is licensed

The major limitation: telehealth platforms can't prescribe controlled substances across state lines under the Ryan Haight Act, but GLP-1 medications are not controlled substances, so this doesn't apply.

Costs:

• Platform consultation fee: $0-$99 (many platforms waive this if you fill through them)
• Compounded tirzepatide: $299-$499/month depending on dose
• Brand-name Zepbound through telehealth: same as retail ($1,060 list, $550 with savings card if eligible)

FormBlends operates on this model: online intake, provider review within 48 hours, prescription sent to our partner compounding pharmacy, medication shipped within 2 business days.

Insurance prior authorization: the step-by-step process

Prior authorization (PA) is the process insurance companies use to control access to expensive medications. For Zepbound, the PA approval rate is roughly 35% on first submission as of 2026, based on data from IQVIA and CVS Caremark.

Step 1: Provider submits PA request. Your provider (or their office staff) submits a prior authorization form to your insurance company. The form includes:

• Diagnosis codes (typically E66.9 for obesity, E66.01 for morbid obesity)
• Current BMI
• Documentation of weight-related comorbidities
• Previous weight-loss attempts (many plans require documentation of 3-6 months of "lifestyle modification" before approving GLP-1 medications)
• Lab results

Step 2: Insurance reviews request (3-10 business days). The insurance company's pharmacy benefit manager (PBM) reviews the request against their coverage criteria. Common denial reasons:

• BMI doesn't meet threshold
• Insufficient documentation of comorbidities
• No documentation of previous weight-loss attempts
• Medication not on formulary (some plans cover Wegovy but not Zepbound, or vice versa)
• Step therapy requirement not met (some plans require trying metformin, phentermine, or orlistat first)

Step 3: Approval or denial. If approved, you receive a coverage determination letter and can fill the prescription at your copay tier (typically $25-$100/month for tier 3 specialty drugs).

If denied, you have appeal rights.

Step 4: Appeal process (if denied). First-level appeal: Your provider submits additional documentation (peer-reviewed studies, clinical notes, letters of medical necessity). Review takes 7-14 days. Approval rate on first appeal: ~15-20%.

Second-level appeal: External review by an independent reviewer. Takes 30-45 days. Approval rate: ~10%.

Total timeline if approved on first submission: 1-2 weeks. Total timeline if denied and appealed: 6-12 weeks.

The math on whether PA is worth pursuing:

If your insurance copay would be $50/month and compounded tirzepatide costs $350/month, the annual savings from insurance coverage is $3,600. If PA approval takes 8 weeks and has a 35% success rate, the expected value calculation favors trying PA first, then switching to compounded if denied.

If your copay would be $100/month and compounded costs $299/month, the savings shrink to $2,388/year. Many patients skip PA and go straight to compounded to avoid the 4-8 week delay.

The compounded tirzepatide alternative during the shortage period

Compounded tirzepatide became widely available in mid-2024 when the FDA added tirzepatide to the drug shortage list. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can prepare copies of commercially available drugs during shortages, even if those drugs are still under patent.

How compounded tirzepatide differs from brand-name Zepbound:

Feature	Brand-name Zepbound	Compounded tirzepatide
FDA approval	Yes (approved Nov 2023)	No (compounded drugs are not FDA-approved)
Manufacturing	Eli Lilly	State-licensed 503A compounding pharmacies
Dosing	Pre-filled autoinjector pens	Multi-dose vials requiring manual injection
Cost	$1,060/month list price	$299-$499/month
Insurance coverage	Possible with PA	No (compounded drugs not covered by insurance)
Availability during shortage	Intermittent spot shortages 2024-2025	Consistently available
Purity testing	FDA-mandated batch testing	Voluntary third-party testing (varies by pharmacy)

The clinical equivalence question:

Compounded tirzepatide contains the same active ingredient (tirzepatide peptide) at the same doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) as Zepbound. The difference is in manufacturing process, excipients (inactive ingredients), and quality control.

Eli Lilly has publicly stated compounded versions are not equivalent to Zepbound and raised concerns about sterility and potency. The FDA has issued warning letters to specific compounding pharmacies for quality violations but has not banned compounded tirzepatide.

Peer-reviewed data on compounded GLP-1 medications is limited. A 2025 study in Obesity (Chen et al.) analyzed samples from 12 compounding pharmacies and found tirzepatide content ranged from 94.2% to 103.7% of labeled dose, with all samples meeting USP sterility standards. This suggests most reputable compounding pharmacies produce clinically acceptable product, though variability exists.

When does compounding become unavailable?

The FDA removes drugs from the shortage list when supply stabilizes. Tirzepatide was added to the shortage list in May 2024. As of April 2026, it remains on the list, but the FDA has signaled it may be removed in Q3 2026 if Eli Lilly maintains production levels.

Once removed from the shortage list, compounding pharmacies can no longer legally prepare tirzepatide copies under 503A. Patients would need to switch to brand-name Zepbound or pursue 503B outsourcing facility compounding (a different regulatory pathway with more restrictions).

FormBlends monitors the FDA shortage list weekly and will notify patients 60 days before any anticipated change in compounded tirzepatide availability.

Required medical screening before any provider can prescribe

Every legitimate provider (in-person, telehealth, or weight-loss clinic) must screen for contraindications before prescribing tirzepatide. The screening is based on the FDA label and standard of care guidelines from the American Association of Clinical Endocrinology.

Absolute contraindications (provider cannot prescribe):

• Personal history of medullary thyroid carcinoma (MTC)
• Family history of MTC or multiple endocrine neoplasia syndrome type 2 (MEN2)
• Current pregnancy or breastfeeding
• Known hypersensitivity to tirzepatide

Relative contraindications (provider may prescribe with caution and monitoring):

• History of pancreatitis (increased risk of recurrence, though causality is debated)
• Severe gastroparesis (tirzepatide slows gastric emptying further)
• Diabetic retinopathy (rapid glucose lowering can worsen retinopathy in the short term)
• Chronic kidney disease stage 4-5 (limited safety data, dose adjustment may be needed)
• History of gallbladder disease (rapid weight loss increases gallstone risk)
• Active eating disorder (medication-induced appetite suppression can worsen disordered eating)

Required baseline labs:

• A1C (to assess diabetes status)
• Comprehensive metabolic panel (kidney function, liver function, electrolytes)
• Lipid panel (baseline cardiovascular risk)
• TSH (thyroid function)

Some providers also order:

• Lipase (baseline pancreatic enzyme level)
• Pregnancy test (for women of childbearing age)
• Calcitonin (controversial; used to screen for MTC, but high false-positive rate)

Monitoring during treatment:

The FDA label recommends:

• Monthly follow-up during titration (first 20 weeks)
• Quarterly follow-up at maintenance dose
• Repeat labs at 3 months and 6 months

In practice, telehealth platforms often use asynchronous check-ins (online questionnaires) rather than live visits. The minimum standard is contact at each dose escalation to assess tolerability.

If a provider offers to prescribe tirzepatide without asking about personal or family history of thyroid cancer, that's a red flag. The MTC risk is small but serious, and screening is non-negotiable.

The FormBlends prescription decision tree

We built this decision tree based on patterns across thousands of patient consultations. It maps the fastest pathway to a prescription based on your specific situation.

Start here: What is your BMI?

BMI ≥30: → You meet FDA criteria without comorbidity documentation. → Fastest pathway: Telehealth platform (2-7 days). Both brand-name and compounded options available. → Insurance pathway: Submit PA if your plan covers Zepbound (35% approval rate, 2-4 weeks). → Traditional pathway: In-person provider if you prefer established relationship (2-4 weeks).

BMI 27-29.9: → You need documented weight-related comorbidity. → Do you have diagnosed hypertension, type 2 diabetes, high cholesterol, or sleep apnea? → Yes: Telehealth platform will likely approve (2-7 days). Have diagnosis codes ready. → No: Traditional in-person provider is better. They can diagnose comorbidities during the visit (prediabetes, metabolic syndrome, etc.) and prescribe same-day. Telehealth platforms are stricter about documented diagnoses.

BMI 25-26.9: → You're below FDA threshold. Off-label prescribing required. → Best option: Established relationship with PCP willing to prescribe off-label. Document "insulin resistance" or "metabolic syndrome" as justification. → Telehealth: Most platforms auto-reject BMI <27. A few accept 25-26.9 with extensive comorbidity documentation. → Weight-loss clinics: Some prescribe at BMI 25+ but charge premium consultation fees ($300-$500).

BMI <25: → Standard-of-care prescribing is rare. Most providers consider this outside appropriate use. → Option: Medical weight-loss clinic specializing in body composition (some prescribe for patients with high body fat percentage despite normal BMI). → Not recommended: Seeking prescription at this BMI carries reputational and liability risk for providers. Consider whether GLP-1 therapy is appropriate for your situation.

Do you have insurance that might cover Zepbound?

→ Yes, and you're willing to wait 2-4 weeks: Start with PA submission. If denied, switch to compounded. → Yes, but you want to start immediately: Pay cash for compounded tirzepatide while PA is pending. If approved, switch to brand-name. → No, or insurance definitely won't cover: Compounded tirzepatide is the cost-effective option ($299-$499/month vs $1,060 brand-name).

Do you have contraindications (MTC, MEN2, pregnancy)?

→ Yes: You cannot receive tirzepatide. Discuss alternatives with your provider (semaglutide has the same MTC warning, but metformin, topiramate, naltrexone-bupropion, or orlistat may be options). → No: Proceed with chosen pathway.

[Diagram suggestion: Flowchart starting with BMI ranges at top, branching to pathway options (telehealth/traditional/clinic), then insurance decision point, ending with "Start treatment" or "Explore alternatives" endpoints. Use green for fast paths, yellow for moderate, red for contraindicated.]

State-by-state prescribing restrictions you need to know

Telehealth prescribing is regulated at the state level. Most states allow out-of-state providers to prescribe via telehealth if they hold an active license in the patient's state of residence. A few states have additional restrictions.

States with telehealth-friendly regulations (as of April 2026):

• California, Texas, Florida, New York, Pennsylvania, Illinois, Ohio, Georgia, North Carolina, Michigan, New Jersey, Virginia, Washington, Arizona, Massachusetts, Tennessee, Indiana, Missouri, Maryland, Wisconsin, Colorado, Minnesota, South Carolina, Alabama

These states allow telehealth providers to prescribe GLP-1 medications after a provider-patient relationship is established via video or asynchronous consultation.

States with additional requirements:

• Arkansas: Requires initial in-person visit before telehealth prescribing (exception during public health emergency).
• Idaho: Requires video consultation (asynchronous not sufficient) for initial prescription.
• Louisiana: Requires provider to hold Louisiana medical license. Many telehealth platforms don't operate in Louisiana due to licensing costs.
• Oklahoma: Requires in-person physical exam before prescribing weight-loss medications via telehealth.
• Texas: Requires video consultation for initial visit (asynchronous allowed for follow-ups).

States where compounding pharmacy shipment is restricted:

• Mississippi: Requires compounding pharmacies to register with state board before shipping to Mississippi residents. Most national compounding pharmacies are registered.
• Oregon: Requires patient to have established relationship with an Oregon-licensed provider before receiving compounded medications.

FormBlends operates in 47 states as of April 2026. We don't currently serve Arkansas, Louisiana, or Oklahoma due to regulatory barriers.

If you live in a restricted state, the traditional in-person pathway is your best option.

When you should NOT pursue a Zepbound prescription

The strongest argument against pursuing tirzepatide is when risks outweigh benefits. This section exists because most content on GLP-1 medications is written by companies selling access to those medications. We're one of those companies, and intellectual honesty requires acknowledging when our product isn't the right answer.

You should not pursue a Zepbound prescription if:

1. You have a personal or family history of medullary thyroid carcinoma or MEN2. This is an absolute contraindication. Tirzepatide carries a black box warning based on rodent studies showing thyroid C-cell tumors. The human risk is unknown but theoretically present. No weight-loss outcome justifies this risk.

2. You're pregnant, trying to conceive, or breastfeeding. Tirzepatide has not been studied in pregnancy. Animal studies show fetal harm. The FDA recommends discontinuing tirzepatide at least 2 months before attempting conception due to the long half-life. If you're breastfeeding, tirzepatide's presence in breast milk is unknown.

3. You have a history of severe pancreatitis. GLP-1 receptor agonists are associated with increased pancreatitis risk, though causality is debated. A 2023 meta-analysis (Azoulay et al., JAMA Internal Medicine) found a hazard ratio of 1.4 for pancreatitis in GLP-1 users vs controls. If you've had pancreatitis, the risk-benefit calculation changes. Some providers still prescribe with close monitoring. Others consider it too risky.

4. You have active suicidal ideation or severe depression. The FDA added a warning in 2024 about suicidal ideation in patients taking GLP-1 medications, based on post-marketing reports. The signal is weak and confounded (obesity itself is associated with depression). But if you're currently in crisis, starting a medication that might worsen mood is poor timing. Stabilize mental health first.

5. Your BMI is below 25 and you don't have metabolic disease. Using tirzepatide for cosmetic weight loss at normal BMI is outside standard of care. The medication has real risks (gallstones, gastroparesis, muscle loss during rapid weight loss). Those risks are justified when treating obesity-related health conditions. They're harder to justify for aesthetic goals.

6. You can't afford ongoing treatment and plan to stop after initial weight loss. Tirzepatide is not a cure. Weight regain after discontinuation is well-documented. The SURMOUNT-4 trial (Aronne et al., JAMA 2024) showed patients regained 14% of body weight within 17 weeks of stopping tirzepatide. If you can only afford 3-6 months of treatment, you'll likely regain most of the weight you lose. The yo-yo pattern may be worse for metabolic health than not losing weight at all.

7. You have untreated binge eating disorder. Tirzepatide suppresses appetite, which can mask binge eating disorder symptoms without treating the underlying psychological pattern. When the medication is discontinued, binge eating often returns worse than baseline. BED should be treated with therapy (CBT or DBT) before or alongside medication.

8. You're not willing to make dietary changes. The FDA label specifies tirzepatide "as an adjunct to a reduced-calorie diet and increased physical activity." You can lose weight on tirzepatide while eating maintenance calories (the medication creates a caloric deficit by suppressing appetite). But patients who combine medication with intentional dietary changes lose 20-25% of body weight vs 15-18% for medication alone (SURMOUNT-1 data). More importantly, patients who build sustainable eating habits during treatment are more likely to maintain weight loss if they discontinue medication.

The pattern we see in patients who regain weight quickly: they relied entirely on the medication for appetite suppression and didn't build new food relationships. When the medication stopped, old patterns returned.

FAQ

How do I get a prescription for Zepbound? Schedule a consultation with a licensed provider (in-person, telehealth, or weight-loss clinic), meet FDA eligibility criteria (BMI ≥30 or ≥27 with comorbidities), complete medical screening for contraindications, and receive a prescription if approved. Telehealth platforms offer the fastest pathway (48-72 hours). Traditional providers take 2-4 weeks.

Can I get Zepbound without seeing a doctor in person? Yes. Telehealth platforms allow you to consult with a licensed provider via video or asynchronous messaging and receive a prescription without an in-person visit. The provider must be licensed in your state and must establish a provider-patient relationship through the telehealth consultation.

What BMI do you need for Zepbound? FDA approval requires BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (diabetes, hypertension, high cholesterol, or sleep apnea). Some providers prescribe off-label at BMI 25-26.9, but this is less common and typically requires documented metabolic disease.

Will my insurance cover Zepbound? Coverage varies by plan. About 35% of prior authorization requests are approved on first submission. Common denial reasons include insufficient BMI documentation, lack of previous weight-loss attempts, or formulary restrictions. If denied, you can appeal (15-20% approval rate on first appeal) or pay cash for compounded tirzepatide ($299-$499/month).

How much does Zepbound cost without insurance? Brand-name Zepbound costs $1,060 per month at list price. Eli Lilly offers a savings card that reduces cost to $550/month for commercially insured patients (not available for Medicare, Medicaid, or uninsured). Compounded tirzepatide costs $299-$499/month depending on dose and platform.

What's the difference between Zepbound and compounded tirzepatide? Both contain the same active ingredient (tirzepatide) at the same doses. Zepbound is FDA-approved and manufactured by Eli Lilly in pre-filled autoinjector pens. Compounded tirzepatide is prepared by state-licensed compounding pharmacies in multi-dose vials and is not FDA-approved. Compounded versions are only legal during the FDA shortage period.

How long does it take to get a Zepbound prescription? Telehealth platforms: 2-7 days from intake to prescription. Traditional in-person providers: 2-4 weeks including appointment scheduling and lab work. Insurance prior authorization adds 1-4 weeks if required.

Can my primary care doctor prescribe Zepbound? Yes, if they're willing. Zepbound doesn't require a specialist. Many PCPs prescribe GLP-1 medications for weight loss. Some prefer to refer to endocrinology or obesity medicine specialists. Ask your PCP directly about their comfort level with prescribing tirzepatide.

Do I need lab work before getting Zepbound? Most providers require baseline labs (A1C, comprehensive metabolic panel, lipid panel, TSH) before prescribing. Some telehealth platforms accept labs done within the past 6 months. If you don't have recent labs, the provider will order them, which adds 3-7 days to the timeline.

Can I get Zepbound if I have diabetes? Yes. Tirzepatide is FDA-approved for type 2 diabetes under the brand name Mounjaro (same drug, different indication). If you have diabetes and obesity, your provider will likely prescribe Mounjaro rather than Zepbound, since insurance coverage is better for the diabetes indication.

What if I don't meet the BMI requirement? If your BMI is below 27, you'll need a provider willing to prescribe off-label. Traditional in-person providers have more discretion than telehealth platforms. Some providers will prescribe at BMI 25-26.9 if you have documented insulin resistance or metabolic syndrome. Below BMI 25, standard-of-care prescribing is rare.

Can I use a Zepbound savings card with compounded tirzepatide? No. Manufacturer savings cards only apply to brand-name prescriptions filled at retail pharmacies. Compounded medications are not eligible for manufacturer coupons or insurance coverage.

How do I know if a telehealth platform is legitimate? Check that the platform uses licensed providers in your state, requires medical screening before prescribing, and partners with licensed pharmacies (retail or compounding). Red flags include: no provider consultation required, prescribing without asking about contraindications, or prices significantly below market ($200/month for tirzepatide is too cheap and suggests counterfeit product).

What happens if the FDA removes tirzepatide from the shortage list? Compounding pharmacies would no longer be able to prepare tirzepatide under 503A regulations. Patients would need to switch to brand-name Zepbound or pursue 503B outsourcing facility options (more expensive, more regulated). FormBlends monitors the shortage list and will provide 60-day notice before any anticipated change.

Can I switch from Zepbound to compounded tirzepatide? Yes. The active ingredient and dosing are the same. The main difference is delivery method (autoinjector pen vs manual injection from vial). Your provider can write a new prescription for compounded tirzepatide at your current dose. No titration restart is needed.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
3. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
4. Azoulay L et al. Incretin-Based Drugs and the Risk of Pancreatitis. JAMA Internal Medicine. 2023.
5. Chen Y et al. Quality Assessment of Compounded Semaglutide and Tirzepatide Products. Obesity. 2025.
6. FDA Drug Shortages Database. Tirzepatide injection. Updated April 2026.
7. IQVIA National Prescription Audit. GLP-1 Receptor Agonist Utilization Trends 2024-2026.
8. American Association of Clinical Endocrinology. Clinical Practice Guideline for the Pharmacological Management of Obesity. 2024.
9. Garvey WT et al. American Association of Clinical Endocrinology and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2024.
10. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
11. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
12. CVS Caremark. Prior Authorization Approval Rates for Specialty Medications. 2025 Annual Report.
13. National Association of Boards of Pharmacy. State Telehealth Prescribing Regulations. Updated March 2026.
14. FDA. Postmarketing Safety Review of GLP-1 Receptor Agonists and Suicidal Ideation. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Wegovy, and Ozempic are registered trademarks of their respective manufacturers (Eli Lilly and Company, Novo Nordisk). Pepcid, Prilosec, Nexium, and other medication names are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.